Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC Pharmacy Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Pharmacy & Specialty Drugs — Coverage Criteria (Formulary ID 25385, Version 18)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists coverage criteria, required medical information, prescriber restrictions, and coverage durations for multiple pharmacy and specialty drugs under the Blue Cross Blue Shield - South Carolina formulary; it affects providers submitting prior authorizations for the listed products.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyCoverage Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 2025
    Last ReviewNov 3, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis-specific documentation and evidence of required trials, biomarker test results, or labs as specified for each product.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12/01/2025effective date
    12 monthstypical coverage duration
    6 monthsinitial duration common
    ~20+products in excerpt
    25385formulary id

    Product-Specific Coverage Criteria

    Actimmune (INJ 100MCG/0.5ML)

    Actimmune coverage

    Actimmune initial coverage: Diagnosis of chronic granulomatous disease (CGD) OR severe malignant osteopetrosis (SMO)

    Coverage duration: 12 months; approve continuation of prior therapy

    Adalimumab family — Initial therapy criteria

    Adalimumab products — indication-specific initial criteria

    RA initial: Diagnosis of moderately to severely active rheumatoid arthritis AND minimum 3-month trial and failure, contraindication, or intolerance (TF/C/I) to one of: methotrexate, leflunomide, or sulfasalazine at maximally tolerated doses

    Prescribed by or in consultation with a rheumatologist; initial duration commonly 6 months

    PJIA initial:
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyCoverage Criteria — Pharmacy & Specialty Drugs
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateDec 1, 2025
    Last ReviewNov 3, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis-specific documentation and evidence of required trials, biomarker test results, or labs as specified for each product.
    SourceLink
    On This Page
    Product-Specific Coverage CriteriaFormulary Identifiers and Key Numeric CriteriaPrior Authorization, Documentation & Denial RisksInitial Authorization RequirementsReauthorization and Continuation RulesStep Therapy and Trial RequirementsSite of Care NotesBackground and ScopeTerms and Diagnostic Test RequirementsPolicy Revision History
    Diagnosis of moderately to severely active polyarticular juvenile idiopathic arthritis AND minimum 6-week TF/C/I to leflunomide or methotrexate at maximally tolerated doses

    Prescriber: rheumatologist; initial duration commonly 6 months

    PsO initial: Diagnosis of moderate to severe chronic plaque psoriasis AND one of: >=3% BSA involvement, severe scalp psoriasis, or palmoplantar/facial/genital involvement AND minimum 4-week TF/C/I to topical therapy (eg, corticosteroid, vitamin D analog, tazarotene, calcineurin inhibitor)

    Prescriber: dermatologist; initial duration commonly 6 months

    AS initial: Diagnosis of active ankylosing spondylitis AND minimum 1-month TF/C/I to an NSAID at maximally tolerated dose

    Prescriber: rheumatologist; initial duration commonly 6 months

    Adalimumab family — Reauthorization

    Adalimumab reauthorization criteria

    General reauth: Patient demonstrates positive clinical response to therapy as evidenced by indication-specific measures (e.g., reduced swollen/tender joint counts, improvement in BSA or symptoms for psoriasis, mucosal healing or improved labs for IBD)

    Reauthorization durations typically 12 months

    Aimovig (erenumab) — Coverage criteria

    Episodic and chronic migraine — Aimovig

    EM initial: Diagnosis of episodic migraine AND at least 4 migraine days per month AND medication will not be used in combination with another CGRP inhibitor for migraine prevention>=4 migraine days/month

    Initial duration 6 months; reauth 12 months

    CM initial: Diagnosis of chronic migraine AND medication overuse headache considered and offending medications discontinued AND at least 8 migraine days per month AND medication will not be used in combination with another CGRP inhibitor>=8 migraine days/month

    Initial duration 6 months; reauth 12 months

    Prolastin-c — Coverage criteria

    Alpha-1 antitrypsin (AAT) augmentation — Prolastin-c

    AAT deficiency initial: Diagnosis of congenital AAT deficiency AND diagnosis of emphysema AND continued conventional treatment for emphysema AND genotype consistent with severe deficiency (eg, PiZZ or other genotypes associated with pre-treatment serum AAT <11 µM/L) AND circulating pre-treatment serum AAT <11 µM/L (or <80 mg/dL by RID or <57 mg/dL by nephelometry), unless necrotizing panniculitis presentpre-treatment serum AAT <11 µM/L (or equivalent)

    Coverage duration 12 months; reauth requires positive clinical response

    PAH / CTEPH agents — Coverage criteria

    Pulmonary arterial hypertension and related agents

    PAH initial: Diagnosis of symptomatic pulmonary arterial hypertension confirmed by right heart catheterization OR patient currently on any therapy for PAH

    Prescriber: pulmonologist or cardiologist; initial duration commonly 6 months; reauth 12 months

    CTEPH initial: Diagnosis of inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension that is symptomatic OR patient currently on any therapy for CTEPH

    Prescriber: pulmonologist or cardiologist; initial duration 6 months; reauth 12 months

    Arformoterol — Coverage criteria

    COPD maintenance

    Arformoterol: Diagnosis of COPD and use for maintenance treatment of bronchoconstriction in COPD (including chronic bronchitis and emphysema)

    Coverage duration 12 months; subject to Part B vs. Part D review

    Augtyro — Coverage criteria

    Tumor molecular marker–driven oncology agents (Augtyro)

    ROS1 NSCLC: Diagnosis of non-small cell lung cancer that is locally advanced or metastatic with ROS1 rearrangement-positive tumor(s)

    Coverage duration 12 months; continuation of prior therapy approved

    NTRK fusion solid tumor: Diagnosis of solid tumor with NTRK gene fusion that is locally advanced, metastatic, or unresectable AND either progressed after previous treatment or has no satisfactory alternative treatments

    Coverage duration 12 months; continuation of prior therapy approved

    Arformoterol — COPD maintenance

    Arformoterol (maintenance treatment) covered when ALL of the following are met

    Arformoterol maintenance therapy criteria: Diagnosis of COPD (including chronic bronchitis and emphysema) and used for maintenance treatment of bronchoconstriction

    Coverage duration: 12 months; subject to Part B vs. Part D review

    Arikayce — refractory MAC lung disease

    Arikayce covered when ALL of the following are met

    Arikayce (amikacin liposome inhalation) criteria: Diagnosis of Mycobacterium avium complex (MAC) lung disease; used as part of a combination antibacterial regimen; patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen

    Prescribed by or in consultation with an infectious disease specialist or pulmonologist; coverage duration 12 months

    Augtyro — ROS1 / NTRK indications

    Augtyro covered when ALL of the following are met

    NSCLC ROS1 and NTRK fusion criteria: Diagnosis of NSCLC that is locally advanced or metastatic with ROS1 rearrangement positive tumor(s) OR solid tumors that are locally advanced, metastatic, or unresectable with NTRK gene fusion; disease progressed following prior treatments or has no satisfactory alternatives

    Coverage duration 12 months; continuation of prior therapy approved

    Avmapki Fakzynja Co-pack — LGSOC with KRAS mutation

    Avmapki Fakzynja Co-pack covered when ALL of the following are met

    Recurrent low-grade serous ovarian cancer (LGSOC) criteria: Diagnosis of recurrent LGSOC; presence of KRAS mutation detected by an FDA-approved or CLIA-performed test; patient has received prior systemic therapy

    Coverage duration 12 months; continuation of prior therapy approved

    Ayvakit — GIST and systemic mastocytosis

    Ayvakit covered when ALL of the following are met

    Ayvakit indications: GIST: unresectable or metastatic with PDGFRA exon 18 mutation (including D842V); AdvSM: diagnosis of ASM, SM-AHN, or MCL with platelet count >50 x10^9/L; ISM with platelet count >50 x10^9/Lplatelets >50 x10^9/L for mastocytosis indications

    Coverage duration 12 months; continuation of prior therapy approved

    Balversa — FGFR3-altered urothelial carcinoma

    Balversa covered when ALL of the following are met

    Urothelial carcinoma with FGFR3 alteration: Diagnosis of locally advanced or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations detected by FDA-approved or CLIA-performed test; disease progressed on or after at least one prior systemic therapy; prior PD-1/PD-L1 therapy given OR patient not candidate for PD-1/PD-L1 therapy

    Coverage duration 12 months; continuation of prior therapy approved

    Benlysta — SLE and lupus nephritis

    Benlysta covered when ALL of the following are met

    Benlysta SLE and Lupus Nephritis initial criteria: SLE (initial): active SLE with positive autoantibody (ANA >=1:80 or anti-dsDNA >=30 IU/mL) and currently receiving at least one standard of care treatment; Lupus nephritis (initial): active lupus nephritis receiving standard of care treatment (eg, corticosteroids with mycophenolate or cyclophosphamide)ANA >=1:80 or anti-dsDNA >=30 IU/mL

    Benlysta IV/SC: patient >=5 years for SLE/lupus nephritis (initial); coverage durations: 6 months for initial/reauthorization; reauth requires positive clinical response

    Besremi — polycythemia vera

    Besremi covered when ALL of the following are met

    Polycythemia vera diagnostic criteria: Diagnosis of polycythemia vera confirmed by either: A) hemoglobin/hematocrit thresholds or increased red cell mass AND bone marrow biopsy showing panmyelosis AND presence of JAK2 or JAK2 exon 12 mutation or subnormal serum erythropoietin, OR B) sustained absolute erythrocytosis with specified hemoglobin/hematocrit thresholds and presence of JAK2 or exon 12 mutation and subnormal serum erythropoietin

    Coverage duration 12 months; continuation of prior therapy approved

    Bosulif — Ph+ CML

    Bosulif covered when ALL of the following are met

    Bosulif CML criteria: Diagnosis of Philadelphia chromosome-positive chronic myelogenous/myeloid leukemia (Ph+ CML)

    Coverage duration 12 months; continuation of prior therapy approved

    Braftovi — BRAF-mutant cancers

    Braftovi covered when ALL of the following are met

    Braftovi oncology indications: Melanoma: unresectable/metastatic with BRAF V600E or V600K mutation; colorectal cancer: BRAF V600E metastatic/unresectable used with cetuximab and prior therapy or with mFOLFOX6; NSCLC: metastatic with BRAF V600E mutation

    Testing by FDA-approved or CLIA lab required; coverage duration 12 months; continuation approved

    Briviact — partial-onset seizures

    Briviact covered when ALL of the following are met

    Briviact partial-onset seizures: Diagnosis of partial-onset seizures; patient is 1 month of age or older

    Coverage duration 12 months; continuation of prior therapy approved

    Bronchitol — cystic fibrosis

    Bronchitol covered when ALL of the following are met

    Bronchitol for cystic fibrosis: Diagnosis of cystic fibrosis and patient has passed the Bronchitol Tolerance Test (BTT); initial age >=18 years for therapy

    Coverage duration: 6 months initial, 12 months reauthorization with demonstrated clinical response

    Brukinsa — lymphoid malignancies

    Brukinsa covered when ALL of the following are met

    Brukinsa hematologic malignancies: MCL with prior therapy or frontline when ineligible for HSCT used with bendamustine+rituximab; WM/LPL; MZL relapsed/refractory after anti-CD20; CLL/SLL; FL relapsed/refractory used with obinutuzumab after >=2 prior systemic therapies

    Coverage duration 12 months; continuation of prior therapy approved

    Exenatide — type 2 diabetes mellitus

    Exenatide (Bydureon, Byetta) covered when ALL of the following are met

    Exenatide T2DM criteria: Initial: documentation of T2DM via chart notes OR laboratory evidence (A1c >=6.5%, FPG >=126 mg/dL, or 2-hour OGTT >=200 mg/dL)A1c >=6.5% or FPG >=126 mg/dL or 2-hour OGTT >=200 mg/dL

    Coverage duration 12 months; reauth requires positive clinical response

    Cablivi — aTTP

    Cablivi covered when ALL of the following are met

    Cablivi aTTP criteria: Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP); first dose administered by healthcare provider as IV bolus; used with immunosuppressive therapy and either with plasma exchange OR patient completed plasma exchange within previous 59 days

    Prescribed by or in consultation with a hematologist/oncologist; coverage duration 3 months

    Cabometyx — multiple oncology indications

    Cabometyx covered when ALL of the following are met

    Cabometyx oncology indications: RCC, HCC with trial/failure/contraindication to sorafenib; DTC in patients >=12 with progression on prior VEGFR-targeted therapy; well-differentiated neuroendocrine tumors unresectable/locally advanced/metastatic after prior therapy

    Coverage duration 12 months; continuation of prior therapy approved

    Calquence — CLL/SLL and MCL

    Calquence covered when ALL of the following are met

    Calquence hematologic indications: MCL (no prior therapy and ineligible for HSCT used with bendamustine+rituximab OR received prior therapy); CLL/SLL

    Coverage duration 12 months; continuation of prior therapy approved

    Caplyta — schizophrenia and bipolar depression

    Caplyta covered when ALL of the following are met

    Caplyta psychiatric indications: Schizophrenia: diagnosis and TF/C/I to two specified oral generic atypical antipsychotics; Bipolar depression: diagnosis of bipolar I or II with depressive episodes and TF/C/I to quetiapine or olanzapine

    Coverage duration 12 months; continuation approved

    Cayston — CF with Pseudomonas aeruginosa

    Cayston covered when ALL of the following are met

    Cayston for CF: Diagnosis of cystic fibrosis and evidence of Pseudomonas aeruginosa in the lungs

    Initial age >=7 years; coverage duration 12 months for initial and reauth; reauth requires clinical benefit (improved FEV1 or fewer exacerbations)

    Cerdelga — Gaucher disease type 1

    Cerdelga covered when ALL of the following are met

    Cerdelga Gaucher disease criteria: Diagnosis of Gaucher disease type 1 and CYP2D6 metabolizer status (EM, IM, or PM) documented by an FDA-cleared test

    Patient >=18 years for this indication; coverage duration 12 months

    Cholbam — bile acid and peroxisomal disorders

    Cholbam covered when ALL of the following are met

    Cholbam bile acid disorders: Bile acid synthesis disorders due to single enzyme defects: diagnosis by abnormal urinary bile acid analysis by MS or molecular genetic testing; Peroxisomal disorders: diagnosis plus at least one clinical feature (liver disease, steatorrhea, or fat-soluble vitamin malabsorption) and used adjunctively

    Initial coverage 4 months, reauth 12 months; reauth requires improvement in liver function

    Ciclopirox nail lacquer — onychomycosis

    Ciclopirox nail lacquer covered when ALL of the following are met

    Ciclopirox onychomycosis criteria: No lunula (matrix) involvement; diagnosis of onychomycosis confirmed by KOH, culture, or histology; if toenail disease, mild to moderate involving at least 1 target toenail; fingernail: TF/C/I to oral terbinafine (>=6 weeks) OR toenail: TF/C/I to oral terbinafine (>=12 weeks)

    Coverage duration 48 weeks

    General product coverage structure

    Covered when ALL of the following are met for specified products (example: Ciclodan/Ciclopirox):

    Example product-level requirements: Diagnosis or medically-accepted indication present; exclusion criteria absent (unless specified); coverage duration as listed; required trials or contraindications met if listed

    This reflects the general product coverage structure; see each product entry for specifics

    Onychomycosis (topical) — Initial

    Onychomycosis topical agents covered when ALL are met:

    Onychomycosis topical criteria: 1) No lunula (matrix) involvement; 2) diagnosis of onychomycosis of toenails or fingernails; 3) diagnostic confirmation via KOH, culture, or histology; 4) if toenail: mild to moderate disease involving at least 1 target toenail; 5) trial and failure/contraindication/intolerance to oral terbinafine (min 6 weeks fingernail, min 12 weeks toenail)

    Coverage duration: 48 weeks

    Hereditary angioedema (prophylaxis)

    C1-INH prophylaxis for HAE covered when ALL are met:

    HAE prophylaxis initial criteria: Diagnosis of hereditary angioedema confirmed by low C1-INH antigenic level OR low C1-INH functional level; indication is prophylaxis against HAE attacks; therapy not used in combination with other approved prophylactic treatments; prescribed by or in consultation with immunologist/allergist for patients >=6 yearsC1-INH antigenic or functional level below LLN

    Initial and reauthorization duration: 12 months; reauth requires positive clinical response

    Schizophrenia — step therapy

    Schizophrenia (specific product) covered when ALL are met:

    Schizophrenia atypical antipsychotic step requirement: Diagnosis of schizophrenia; trial and failure/contraindication/intolerance to two oral generic formulary atypical antipsychotics (aripiprazole, asenapine, olanzapine, paliperidone, quetiapine IR/ER, risperidone, ziprasidone)

    Coverage duration 12 months; continuation of prior therapy approved

    Cosentyx and related biologics — psoriasis and rheumatologic indications

    Cosentyx and related biologics coverage conditions (psoriasis, PsA, AS, nr-axSpA, ERA, HS):

    Plaque psoriasis initial: Diagnosis of moderate to severe plaque psoriasis with >=3% BSA or severe scalp/palmoplantar/facial/genital involvement; minimum 4-week TF/C/I to topical therapy; prescribed by or in consultation with a dermatologist; initial coverage 6 months; reauth 12 months with documented clinical response4-week topical trial; >=3% BSA
    Psoriatic arthritis initial: Diagnosis of active PsA (inflamed joints, dactylitis, enthesitis, axial disease, or active skin/nail involvement); trial and failure/contraindication/intolerance to specified systemic or biologic agents as listed OR continuation of prior therapy; prescribed or in consultation with rheumatologist or dermatologist; initial 6 months; reauth 12 months with documented response

    Cotellic — oncology indications

    Cotellic coverage for melanoma and histiocytic neoplasm:

    Cotellic melanoma: Unresectable or metastatic melanoma AND BRAF V600E or V600K mutation detected by FDA-approved or CLIA-performed test AND used in combination with vemurafenib

    Coverage duration 12 months

    Cotellic histiocytic neoplasm: Diagnosis of histiocytic neoplasm AND used as monotherapy

    Coverage duration 12 months

    Deferasirox — iron overload

    Deferasirox coverage conditions by indication:

    Transfusional iron overload initial: Diagnosis of chronic iron overload due to blood transfusions; baseline ferritin >1,000 mcg/L; required transfusion of >=100 mL/kg PRBCs; age >=2 yearsbaseline ferritin >1,000 mcg/L

    Coverage duration initial and reauth: 12 months; reauth requires reduction in ferritin or LIC

    MDS initial: Diagnosis of myelodysplastic syndrome with Low or Intermediate-1 disease or potential transplant patient and >20 RBC transfusions

    Coverage duration initial and reauth: 12 months; reauth requires reduction in ferritin or LIC

    NTDT initial: Diagnosis of chronic iron overload due to NTDT with LIC >=5 mg Fe/g dw OR serum ferritin >300 mcg/L; age >=10 years for initialLIC >=5 mg Fe/g dw or ferritin >300 mcg/L

    Initial and reauth durations noted; reauth criteria include LIC >=3 mg Fe/g dw and reduction from baseline

    Metyrosine — pheochromocytoma

    Metyrosine coverage for pheochromocytoma (preop and treatment):

    Preoperative preparation: Biochemical confirmation of pheochromocytoma by plasma free metanephrines OR urinary fractionated metanephrines; medication used for preoperative preparation; trial and failure/intolerance/contraindication to both an alpha-adrenergic blocker and a beta-adrenergic blocker; prescribed by or in consultation with endocrinologist or endocrine surgeon

    Coverage duration: 4 weeks for preop preparation

    Treatment of pheochromocytoma initial: Biochemical confirmation of pheochromocytoma; hormonally active pheochromocytoma not surgical candidate or chronic malignant disease; inadequate response to selective alpha-1 blocker plus beta blocker; prescribed by or in consultation with endocrinologist; initial coverage 6 months; reauth 12 months with positive clinical response

    Doptelet — hematology indications

    Doptelet coverage by indication:

    TPPP (thrombocytopenia prior to planned procedure): Diagnosis of thrombocytopenia in chronic liver disease with scheduled procedure and baseline platelet count <50,000/mcLplatelet count <50,000/mcL

    Coverage duration: 1 month

    ITP initial: Diagnosis of chronic ITP, relapsed/refractory ITP, or persistent pediatric ITP with baseline platelet count <30,000/mcL and trial and failure/contraindication/intolerance to at least one of corticosteroids, IVIG, or splenectomyplatelet count <30,000/mcL

    Prescribed by or in consultation with hematologist/oncologist; coverage duration initial and reauth: 12 months; reauth requires platelet response

    Diacomit (fenfluramine) — Dravet syndrome

    Diacomit (fenfluramine) — Dravet syndrome

    Diacomit initial: Diagnosis of seizures associated with Dravet syndrome (DS); used in combination with clobazam; patient weighs >=7 kg; age >=6 monthsage >=6 months; weight >=7 kg

    Prescribed by or in consultation with a neurologist; coverage duration 12 months; continuation approved

    Doptelet (avatrombopag) — ITP and TPPP

    Doptelet (avatrombopag) — ITP and TPPP

    TPPP: Diagnosis of thrombocytopenia in chronic liver disease scheduled for procedure and baseline platelet count <50,000/mcLplatelet count <50,000/mcL

    Coverage duration 1 month

    ITP initial: Diagnosis of chronic/relapsed/refractory or pediatric persistent ITP with baseline platelet count <30,000/mcL and TF/C/I to corticosteroids, IVIG, or splenectomyplatelet count <30,000/mcL

    Prescribed by/consult with hematologist/oncologist; coverage duration 12 months; reauth requires platelet response

    Dulera — Asthma

    Dulera — Asthma

    Asthma initial: Diagnosis of asthma and trial and failure/contraindication/intolerance to Breo Ellipta (fluticasone furoate/vilanterol)

    Age >=5 years for initial; coverage duration 12 months; reauth requires positive clinical response

    Dupixent (dupilumab) — multiple indications

    Covered when indication-specific criteria are met

    Eosinophilic asthma (init): Diagnosis of moderate-to-severe eosinophilic asthma with baseline blood eosinophils >=150 cells/mcL AND either >=2 exacerbations requiring systemic corticosteroids in past 12 months OR prior asthma-related hospitalization in past 12 monthsblood eosinophils >=150 cells/mcL

    Age >=6 years for some indications; prescriber specialty requirements apply; coverage durations vary by indication

    COPD (init): Diagnosis of COPD with type 2 inflammation (baseline eosinophils >=300 cells/mcL), on maximally tolerated triple therapy or LAMA+LABA if ICS contraindicated, and >=2 exacerbations requiring systemic corticosteroids or COPD-related hospitalization in past 12 monthsblood eosinophils >=300 cells/mcL

    Coverage duration initial 6 months for some indications; reauth 12 months

    EoE (init): Diagnosis of eosinophilic esophagitis with symptoms of esophageal dysfunction, >=15 intraepithelial eosinophils per high power field, exclusion of other causes, patient weight >=15 kg, and TF/C/I to an 8-week PPI or topical esophageal corticosteroid>=15 eosinophils/HPF

    Coverage 12 months; reauth requires positive clinical response by symptoms, histology, or endoscopy

    Emgality (galcanezumab) — migraine and cluster headache

    Emgality (galcanezumab) — migraine and cluster headache

    Episodic migraine (init): Diagnosis of episodic migraine; at least 4 migraine days per month; not used with another CGRP inhibitor>=4 migraine days/month

    Initial coverage 6 months; reauth 12 months with demonstrated positive response

    Chronic migraine (init): Diagnosis of chronic migraine; medication overuse considered and offending meds discontinued; at least 8 migraine days per month; not used with another CGRP inhibitor>=8 migraine days/month

    Initial coverage 6 months; reauth 12 months

    Episodic cluster headache (init): Diagnosis of episodic cluster headache with at least 2 cluster periods lasting 7–365 days separated by >=3 months pain-free; not used with another injectable CGRP inhibitor>=2 cluster periods

    Initial coverage 3 months; reauth 12 months if positive response

    Empaveli (pegcetacoplan) — PNH and glomerulopathies

    Empaveli (pegcetacoplan) — PNH and glomerulopathies

    PNH (init): Diagnosis of paroxysmal nocturnal hemoglobinuria

    Prescribed by or in consultation with hematologist/oncologist; coverage 12 months; reauth requires positive clinical response

    C3G or primary IC-MPGN (init): Diagnosis of C3G or primary immune-complex MPGN; for primary IC-MPGN, patient has not had a kidney transplant and has been treated with maximally tolerated ACEi/ARB or SGLT2 inhibitor for >=12 weeks prior to initiation12 weeks prior maximally tolerated therapy

    Prescribed/consult with nephrologist; age >=12 years for these indications; coverage 12 months; reauth requires positive clinical response

    Enbrel (etanercept) — rheumatologic and dermatologic indications

    Enbrel (etanercept) — rheumatologic and dermatologic indications

    Rheumatoid arthritis (init): Diagnosis of moderately to severely active RA and trial of at least one conventional DMARD (methotrexate, leflunomide, sulfasalazine) for >=3 months at maximally tolerated doses3 months trial

    Prescriber or consult with rheumatologist; initial coverage 6 months; reauth 12 months with evidence of positive clinical response

    Plaque psoriasis (init): Moderate to severe chronic plaque psoriasis with >=3% BSA involvement or severe scalp/palmoplantar/facial/genital involvement and trial/failure of topical therapies for >=4 weeks4-week topical trial

    Prescriber/consult with dermatologist; initial 6 months; reauth 12 months with documented clinical response

    Ankylosing spondylitis (init): Active AS and trial/failure/intolerance to one NSAID for >=1 month1 month NSAID trial

    Prescriber/consult with rheumatologist

    L-glutamine — sickle cell disease

    Covered when ALL of the following are met

    Sickle cell disease (init): Diagnosis of sickle cell disease and history of >=2 painful sickle cell crises within past 12 months>=2 crises in 12 months

    Coverage 12 months; reauth requires positive clinical response

    Ensacove (brigatinib?) — ALK-positive NSCLC

    Ensacove (brigatinib?) — ALK-positive NSCLC

    NSCLC ALK+ (init): Diagnosis of locally advanced or metastatic NSCLC that is ALK rearrangement-positive by FDA-approved or CLIA-performed test, and patient has not previously received an ALK inhibitor

    Coverage duration 12 months; approve continuation of prior therapy if already on drug

    Epidiolex (cannabidiol) — seizure disorders

    Epidiolex (cannabidiol) — seizure disorders

    Lennox-Gastaut syndrome: Diagnosis of seizures associated with LGS and trial/failure/contraindication/intolerance to two formulary anticonvulsants (e.g., topiramate, lamotrigine, valproate)

    Age >=1 year; neurologist consult required; coverage 12 months; continuation approved

    Dravet syndrome: Diagnosis of seizures associated with Dravet syndrome

    Age >=1 year; neurologist consult required; coverage 12 months

    Tuberous sclerosis complex (TSC) seizures: Diagnosis of seizures associated with TSC

    Age >=1 year; neurologist consult required; coverage 12 months

    Procrit (epoetin alfa) — anemia indications

    Procrit (epoetin alfa) — anemia indications

    Anemia with CKD (initial): Diagnosis of CKD with anemia by labs (Hct <30% or Hgb <10 g/dL) collected within 30 days AND either patient is on dialysis without ESRD OR not on dialysis and rate of Hgb decline indicates likely need for transfusionHct <30% or Hgb <10 g/dL within 30 days

    Coverage criteria vary by scenario; see reauth rules

    Anemia with chemo (initial): Non-myeloid malignancy receiving chemotherapy; other causes of anemia ruled out; anemia by labs (Hct <30% or Hgb <10 g/dL) within prior 2 weeksHct <30% or Hgb <10 g/dL within 2 weeks

    Coverage applies if criteria met

    Anemia with HIV (initial): Anemia by labs (Hgb <12 g/dL or Hct <36%) within 30 days, serum erythropoietin <=500 mU/mL, patient receiving zidovudine therapy or diagnosis of HIVEPO <=500 mU/mL; Hgb <12 g/dL or Hct <36%

    Coverage when documented

    Anemia in MDS (initial): Diagnosis of MDS with serum erythropoietin <=500 mU/mLEPO <=500 mU/mL

    Coverage when documented

    Anemia — CKD initial

    Erythropoiesis-stimulating or anemia-related drug indications (selected examples)

    Anemia with CKD (Initial): Diagnosis of CKD AND anemia by labs (Hct <30% or Hgb <10 g/dL) within 30 days of request AND (a) patient is on dialysis and without ESRD OR (b) patient is not on dialysis AND rate of Hgb decline indicates likelihood of requiring RBC transfusionHct <30% or Hgb <10 g/dL

    From Procrit entry (chunk 72)

    Anemia — HIV and MDS initial

    Anemia associated with HIV or MDS (selected examples)

    Anemia with HIV (Initial): Anemia by Hgb <12 g/dL or Hct <36% within 30 days; serum erythropoietin <=500 mU/mL; receiving zidovudine therapy or diagnosis of HIVHgb <12 g/dL or Hct <36%

    From chunk 73

    MDS (Initial): Diagnosis of MDS; serum erythropoietin <=500 mU/mLEPO <=500 mU/mL

    From chunk 73

    Anemia — reauthorization

    Reauthorization rules for anemia indications

    CKD (Reauth): One of: most recent or average Hct over 3 months <=33% (on dialysis, without ESRD) OR <=30% (not on dialysis) OR <=36% for pediatric patients; patient demonstrates positive clinical response vs pre-treatmentHct thresholds by dialysis status

    Reauth durations typically 12 months

    ref":"b0_52","title":"Anemia — reauthorization"},{

    Formulary Identifiers and Key Numeric Criteria

    Formulary identifiersmixed
    Formulary ID: 25385Formulary identifier for listed products
    Formulary identifiersmixed
    Formulary ID: 25385Formulary identifier applied to listed products
    Formulary identifiersmixed
    Formulary ID: 25385Formulary identifier for listed products (Version 18)
    Formulary Identifiersmixed
    Formulary ID: 25385Formulary identifier repeated across entries
    Formulary identifiermixed
    Formulary ID: 25385Formulary identifier repeated for listed products
    inv-211: Migraine frequency
    Episodic migraine (EM)>= 4 migraine days per month
    Chronic migraine (CM)>= 8 migraine days per month
    Preventive CGRP useNot used in combination with another injectable CGRP inhibitor for prevention
    inv-212: AAT serum level
    Pre-treatment serum AAT< 11 µM/L
    Equivalent by radial immunodiffusion (RID)< 80 mg/dL
    Equivalent by nephelometry< 57 mg/dL
    inv-213: A1c / FPG / 2-hour OGTT
    Hemoglobin A1c (A1c)>= 6.5%
    Fasting plasma glucose (FPG)>= 126 mg/dL
    2-hour OGTT plasma glucose>= 200 mg/dL
    inv-214: ANA / anti-dsDNA criteria
    ANA titer>= 1:80
    Anti-dsDNA>= 30 IU/mL
    inv-215: Polycythemia vera hemoglobin/hematocrit thresholds
    Hemoglobin thresholds>16.5 g/dL (men) or >16.0 g/dL (women)
    Hematocrit thresholds>49% (men) or >48% (women)
    Alternate sustained erythrocytosis criteriaHigher cutpoints (eg, Hgb >18.5 g/dL or Hct >55.5%) per diagnostic branch
    inv-216: Ferritin (transfusional iron overload)
    Baseline ferritin (transfusional iron overload)> 1,000 mcg/L
    Transfusion history requirementRequired transfusion of >=100 mL/kg packed RBCs for transfusional iron overload
    NTDT ferritin noteNTDT criteria reference: serum ferritin >300 mcg/L for some NTDT entries
    inv-217: LIC (NTDT initial)
    LIC (NTDT) — initial>= 5 mg Fe/g dw
    Age considerationInitial NTDT: age >=10 years (per deferasirox entry)
    Reauth requirement noteReauth requires reduction in ferritin or LIC from baseline
    inv-218: LIC (NTDT reauth)
    LIC (NTDT) — reauthorization>= 3 mg Fe/g dw
    Reauth evidenceReauth: documented reduction in ferritin or LIC from baseline
    Initial vs reauth durationsInitial NTDT coverage noted as 6 months; reauth conditions apply
    inv-219: Platelet count (TPPP)
    TPPP baseline platelet count< 50,000/mcL
    IndicationThrombocytopenia in chronic liver disease prior to planned procedure
    Coverage duration (TPPP)1 month (per Doptelet entry)
    inv-220: Platelet count (ITP)
    ITP baseline platelet count< 30,000/mcL
    Prior therapy requirementTrial/failure/contraindication/intolerance to corticosteroids, IVIG, or splenectomy
    PrescriberPrescribed by or in consultation with hematologist/oncologist

    Prior Authorization, Documentation & Denial Risks

    Prior Authorization

    Prior authorization with diagnosis and trial/failure documentation

    Submit a prior authorization that includes the member’s diagnosis and documentation of required prior trials or failures when specified; approvals are indication‑specific and often require specialty prescriber information and objective supporting data.

    • Include diagnosis documentation for the requested indication.
    • Provide evidence of trials/failures, contraindications, or intolerance to required prior therapies (TF/C/I) when listed.
    • Note prescriber specialty or consultation when required (eg, rheumatologist, pulmonologist, infectious disease).
    Prior Authorization

    Prior authorization required

    A prior authorization is required for these products; do not assume auto‑approval — submit clinical records demonstrating the diagnosis and indication‑specific criteria.

    • PA is product‑level and required for each entry (Formulary ID: 25385).
    • Coverage durations and clinical requirements are specified per product.
    Prior Authorization

    Product-level prior authorization

    Each product entry is subject to a product‑level prior authorization — include the exact required medical information and note the listed coverage duration.

    • Formulary identifier applies to entries (Formulary ID: 25385).
    • Verify and include any exclusion criteria (eg, concurrent nitrates where noted).
    Prior Authorization

    Prior authorization required

    Submit a prior authorization with indication‑specific clinical data, prescriber specialty, age limits, and evidence of prior therapy trials or contraindications as specified for the drug and indication.

    • Include age and prescriber specialty when required (eg, CF specialist, pulmonologist, neurologist).
    • Attach objective measures (labs, imaging, mutation testing) when requested.
    Prior Authorization

    Prior authorization required with supporting clinical data

    Provide supporting objective clinical data with the prior authorization — labs, diagnostic testing, genetic or biomarker results, and prior therapy details are required when listed.

    • When biomarkers are required, submit FDA‑approved or CLIA lab reports.
    • Include recent laboratory values (eg, Hgb/Hct, ferritin, A1c) within the timeframe specified.
    Prior Authorization

    Prior authorization: diagnosis and supporting info required

    For many targeted and oncology agents, prior authorization must include the specified diagnosis and the supporting clinical information (staging, mutation/fusion test results, prior systemic therapy) as listed for the product.

    • Attach documentation of tumor mutation status or biomarker testing when required.
    • Document prior systemic therapies and lines of treatment where specified.
    Prior Authorization

    Prior authorization requirement

    Include diagnostic results, biomarker or molecular testing, and prior therapy history in the prior authorization; coverage durations are commonly 12 months unless otherwise noted.

    • When a companion diagnostic is required, submit the FDA‑approved assay or CLIA lab report.
    • State initial authorization duration and plan for reauthorization documentation.
    Prior Authorization

    Prior authorization and documentation

    Attach documentation of diagnosis, prior therapies (when specified), and any relevant genetic/molecular test results performed by an FDA‑approved or CLIA‑certified laboratory as part of the PA submission.

    • Ensure molecular testing reports (eg, KRAS, PIK3CA, EGFR, BRAF) are included when required.
    • Document stage/extent of disease for oncology indications.
    Prior Authorization

    Braftovi combination — PA requirement

    For BRAF‑mutant melanoma or NSCLC requests, submit documentation of the BRAF V600E or V600K mutation detected by an FDA‑approved test (THxID‑BRAF Kit) or a CLIA‑approved laboratory and confirm combination use with encorafenib where required.

    • Provide the mutation test report and the treatment plan showing combination therapy with encorafenib.
    Prior Authorization

    Armodafinil — PA and reauth

    Armodafinil prior authorization requires diagnostic confirmation (eg, sleep study for OSA or narcolepsy unless justification is provided) and documentation of response for reauthorization.

    • If OSA, submit sleep study showing ≥15 events/hour or ≥5 events/hour with symptoms unless justified.
    • Document symptomatic benefit at reauthorization.
    Prior Authorization

    Prior authorization required

    Prior authorization requires documentation of diagnosis and prior treatment details (for example, prior intensive induction chemotherapy and achievement of CR/CRi for AML‑maintenance agents).

    • Attach records verifying prior induction regimen and CR/CRi status.
    • State inability to pursue further intensive curative therapy when applicable.
    Prior Authorization

    PAH prior authorization

    For PAH therapies (eg, Opsumit, Orenitram), include confirmation of PAH by right heart catheterization or documentation that the patient is currently on PAH therapy, and ensure initial prescribing involves a pulmonologist or cardiologist.

    • Submit right heart cath report or documentation of current PAH therapy.
    • Indicate the specialty prescriber on the request.
    Prior Authorization

    Prior authorization and duration

    Prior authorization and reauthorization require documentation of diagnosis and prior treatment history; authorization durations vary by product (commonly 6 months initial, 12 months reauthorization).

    • State initial and intended authorization durations.
    • Provide objective measures for reauthorization as required.
    Prior Authorization

    Prior authorization and coverage duration

    Include indication, prior therapy trials as specified, prescriber specialty when required, and age limits in the PA; many products authorize initial coverage for 6 months and reauthorization for 12 months unless noted otherwise.

    • Confirm age and prescriber specialty.
    • Attach evidence of TF/C/I to required prior agents.
    Prior Authorization

    Prior authorization requirement

    Submit a prior authorization that documents the specific diagnosis, demonstrates the patient meets indication‑specific severity/step criteria (including weight or age limits where listed), and includes specialty prescriber information when required.

    • For biologics, include severity metrics (eg, BSA, CDAI) where required.
    • Include weight or age documentation for formulations with thresholds.
    Prior Authorization

    Osteoporosis therapies PA

    For osteoporosis therapies (Tymlos, teriparatide and similar), prior authorization must include BMD T‑scores, fracture history, and documentation of trial and failure/contraindication/intolerance to prior osteoporosis treatments or FRAX scores where applicable.

    • Provide lumbar spine, femoral neck, total hip, or one‑third radius BMD T‑scores.
    • Include FRAX 10‑year probabilities when requested (major ≥20% or hip ≥3%).
    Prior Authorization

    Trulicity PA

    Trulicity (and related GLP‑1 agents) prior authorization requires submission of medical records confirming type 2 diabetes mellitus or qualifying laboratory evidence (A1c ≥6.5% or FPG ≥126 mg/dL or OGTT criteria).

    • Attach chart notes or lab reports (A1c, FPG, or OGTT) supporting T2DM diagnosis.
    • Document prior diabetes management as applicable.
    Prior Authorization

    Lapatinib prior authorization

    Lapatinib prior authorization must include documentation of HER2‑positive advanced/metastatic/recurrent breast cancer and the concomitant agent to be used (trastuzumab, capecitabine, or an aromatase inhibitor).

    • Provide pathology or testing confirming HER2 positivity and treatment plan showing combination agent.
    • Coverage commonly authorized for 12 months.
    Prior Authorization

    Vyvgart Hytrulo prior authorization

    Vyvgart Hytrulo PA requires documentation of anti‑AChR antibody‑positive generalized myasthenia gravis and evidence of trial and failure (or contraindication/intolerance) to the required immunosuppressive therapies or plasmapheresis/IVIG per the criteria.

    • Include antibody testing confirming anti‑AChR positivity.
    • Document TF/C/I to two immunosuppressive agents or one agent plus IVIG/plasmapheresis.
    Step Therapy

    Conventional therapy trial required

    Many biologic and specialty drug indications require documentation of trial and failure, contraindication, or intolerance (TF/C/I) to conventional therapies at maximally tolerated doses before approval.

    • Document the specific agents tried, durations, and reasons for failure/intolerance.
    • If continuing prior therapy, indicate prior authorization history.
    Step Therapy

    Caplyta prior trial requirement

    For Caplyta requests, document trial and failure, contraindication, or intolerance to two listed generic atypical oral antipsychotics prior to approval.

    • List the two antipsychotics tried and provide clinical notes showing inadequate response or intolerance.
    • Include diagnosis (schizophrenia or bipolar disorder) per product criteria.
    Step Therapy

    Tadalafil BPH prior therapy requirement

    For tadalafil for BPH, include documentation of trial and failure, contraindication, or intolerance to an alpha‑blocker or a 5‑alpha reductase inhibitor as required by the PA criteria.

    • Document which alpha‑blocker or 5‑alpha reductase inhibitor was tried and reason for failure or intolerance.
    • Include BPH diagnosis in submitted records.
    Step Therapy

    Step therapy and trial/failure requirements

    Many products require trial and failure of specified agents before approval (step‑therapy); submit documentation of the exact comparators tried and the clinical rationale for failure/intolerance.

    • For dermatology and psychiatric agents, list topical/systemic agents tried and durations.
    • For biologics, provide evidence of prior DMARDs or TNF inhibitor trials where required.
    Step Therapy

    Step therapy / prior trial requirements

    Submit documentation of TF/C/I to specified prior therapies (examples include inhaled controller optimization for biologic asthma agents or maximal ACEi/ARB/SGLT2 background for certain nephrology indications) when step requirements are listed.

    • Summarize prior medication history and reasons for discontinuation or failure.
    • Provide objective measures (exacerbation history, lab values) supporting the need for escalation.
    Step Therapy

    Concurrent therapy restriction (Evrysdi)

    Do not combine Evrysdi with other chronic SMN‑modifying therapies; if prior gene therapy was given, provide documentation of inadequate response to support approval.

    • State whether the patient has received prior gene therapy (eg, Zolgensma) and, if so, include objective evidence of inadequate response.
    • Confirm absence of concomitant chronic SMN‑modifying therapy.
    Step Therapy

    Step therapy / trials required

    Many agents require documented trial and failure/contraindication/intolerance to specified conventional therapies prior to approval — include dates, doses, and clinical notes demonstrating inadequate response.

    • For anti‑seizure, oncology, and immunologic agents, provide prior therapy history with objective assessments of response.
    • If exempt (continuation of prior therapy), include prior authorization records.
    Step Therapy

    Step therapy / trial requirements

    Several agents require trial and failure/contraindication/intolerance to specified prior therapies (eg, terbinafine before itraconazole for onychomycosis or at least one DMT prior to Kesimpta); include trial duration and outcome.

    • Provide lab or test confirmation (eg, KOH/culture) as required by the indication.
    • Document durations of prior systemic/topical therapies and reasons for failure.
    Step Therapy

    Required prior systemic therapy

    Some oncology approvals require prior use of specific chemotherapies or targeted agents before considering the listed product; include prior regimens and dates.

    • List prior lines of systemic therapy and supportive documentation (infusion records, oncology notes).
    • For combination approvals, show planned or concurrent agents.
    Step Therapy

    Opipza step requirements

    Opipza approvals require documentation of TF/C/I to the listed prior antipsychotics (number varies by indication); provide evidence of trials and outcomes.

    • For schizophrenia: document two failed or intolerant atypical antipsychotics.
    • For MDD or autism irritability, include the specific agents and trial details per criteria.
    Step Therapy

    Opusmit step requirements

    Opusmit and similar antipsychotic entries require trial and failure or intolerance to specified listed agents (commonly two agents for schizophrenia); include medication lists and clinical justification.

    • Attach prior psychiatry notes documenting inadequate response or intolerance.
    • If clozapine was used, include rationale and response.
    Step Therapy

    Required prior therapy trials

    Some hematology products (eg, eltrombopag) require failure or intolerance to corticosteroids, IVIG, or splenectomy prior to approval; include hematology consultation notes and baseline labs.

    • Provide baseline platelet counts and prior treatment dates/outcomes.
    • Include hematologist recommendation when available.
    Step Therapy

    Required prior therapy trials

    Many dermatologic and rheumatologic therapies require TF/C/I to topical or systemic comparator therapies (topical corticosteroids, tacrolimus, TNF inhibitors, conventional DMARDs); provide trial details and clinical response measures.

    • Document topical/systemic trial durations and objective severity (BSA, SCORAD).
    • If contraindicated to comparators, include rationale in the chart notes.
    Step Therapy

    Trial and failure requirements

    For agents that require trial/failure of alternatives (eg, penicillamine before trientine; one osteoporosis therapy before teriparatide), include records of the prior agent and the reason therapy failed or was not tolerated.

    • Provide dates, doses, and adverse event documentation or lack of efficacy.
    • Include specialist notes supporting the step exemption when applicable.
    Step Therapy

    TF/C/I requirements

    Many oncology and specialty drugs require TF/C/I to listed alternatives; include documentation of each prior agent tried and the clinical reason for discontinuation.

    • Summarize prior lines of therapy succinctly in the PA cover letter.
    • Attach supporting oncology clinic notes or infusion records.
    Step Therapy

    Tymlos step therapy

    Tymlos prior authorization requires documentation of BMD T‑scores and either fracture history or TF/C/I to prior osteoporosis therapy for the applicable criteria set; observe the lifetime parathyroid hormone duration limit.

    • Provide BMD reports and prior osteoporosis therapy history.
    • Confirm total parathyroid hormone treatment will not exceed 24 months lifetime.
    Step Therapy

    Ubrelvy step therapy

    Ubrelvy for acute migraine requires documentation of trial and failure or intolerance to one triptan (or contraindication to all triptans) before approval.

    • Include which triptan was tried and clinical notes showing inadequate response or intolerance.
    • Confirm acute (not preventive) use and age ≥18.
    Step Therapy

    Vyvgart Hytrulo step therapy

    Vyvgart Hytrulo requires documentation of trial and failure or contraindication/intolerance to two immunosuppressive therapies (or one immunosuppressive therapy plus plasmapheresis/IVIG) before approval for gMG.

    • Provide records of immunosuppressive agents tried and response.
    • If plasmapheresis/IVIG used, include dates and response documentation.
    Documentation Required

    Required clinical documentation

    Provide the required clinical documentation with the PA: diagnosis documentation, lab results, imaging, biomarker/molecular testing, and prior therapy history per the product‑specific requirements.

    • Include copies of lab reports, imaging, pathology, and genetic/molecular testing.
    • Chart notes should show clinical course and rationale for the requested therapy.
    Documentation Required

    Submission of medical records for T2DM

    For diabetes GLP‑1 and similar agents (eg, exenatide, Ozempic), submit medical records or lab evidence confirming type 2 diabetes mellitus (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour OGTT ≥200 mg/dL) as part of the PA.

    • Attach the most recent A1c or fasting plasma glucose/OGTT results.
    • Include diabetes treatment history and target glycemic goals.
    Documentation Required

    Arikayce documentation of treatment failure

    For Arikayce requests for MAC lung disease, include documentation that the patient did not achieve at least two negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen and provide infectious disease or pulmonology specialist notes.

    • Attach sputum culture history showing persistent positive cultures despite ≥6 months of background therapy.
    • Include the specialist consultation note and regimen details.
    Documentation Required

    Onychomycosis required documentation

    For topical onychomycosis products (eg, ciclopirox nail lacquer), submit confirmation of diagnosis (KOH, culture, or histology), documentation that the lunula (nail matrix) is not involved, and evidence of trial and failure/contraindication/intolerance to oral terbinafine for the required duration.

    • Include KOH, fungal culture, or histology reports.
    • Document terbinafine trial duration (≥6 weeks fingernail, ≥12 weeks toenail) or reason for contraindication.
    Documentation Required

    Iron overload required documentation

    For deferasirox (iron overload), submit baseline ferritin >1,000 mcg/L and transfusion history (≥100 mL/kg PRBCs) or LIC data for NTDT per the initial/reauthorization criteria.

    • Provide baseline ferritin and transfusion volume history.
    • Include LIC measurements where applicable (NTDT thresholds).
    Documentation Required

    Doptelet required documentation

    For Doptelet in ITP/TPPP, include baseline platelet count and documentation of planned procedure (TPPP) or prior TF/C/I to corticosteroids/IVIG/splenectomy for ITP, plus hematology consultation notes.

    • Attach baseline platelet count (<50,000 for TPPP; <30,000 for ITP).
    • Provide procedure scheduling for TPPP or prior therapy documentation for ITP.
    Documentation Required

    Required laboratory documentation

    Lab documentation is required for anemia and related indications — submit recent Hgb/Hct values within the specified timeframe and erythropoietin levels when applicable.

    • Include Hgb/Hct within 30 days (CKD) or within 2 weeks (chemotherapy) as specified.
    • Attach serum erythropoietin when required (≤500 mU/mL for some indications).
    Documentation Required

    Baseline biomarker / diagnostic documentation

    For biologics and other specialty agents that require baseline biomarkers or diagnostic testing (eg, blood eosinophils for eosinophilic asthma; histology for EoE), include the baseline test results with the PA.

    • Attach blood eosinophil counts, biopsy/histology reports, HRCT, or other baseline biomarkers as required.
    • Document any prior therapy optimization steps (eg, inhaled controller optimization).
    Documentation Required

    Required medical information

    Submit medical records that document diagnosis, prior therapy trials/failures, and supporting labs/tests per the indication (examples: Hgb/Hct, HRCT/biopsy for IPF, or genetic testing for inherited disease).

    • Provide clear, dated clinical notes tying objective results to the request.
    • Include specialist consult notes where required.
    Documentation Required

    Required diagnostic test evidence

    When diagnostic testing is required (EGFR, HER2, ROS1, KRAS, PIK3CA, MET, BRAF), include the test report performed by an FDA‑approved assay or a CLIA‑certified laboratory as part of the PA.

    • Attach the molecular/pathology report showing the detected mutation/fusion.
    • Specify the assay and performing laboratory (FDA‑approved or CLIA‑certified).
    Documentation Required

    Required clinical documentation

    Provide diagnosis, required biomarker/mutation test results (from FDA‑approved or CLIA labs), and prior therapy history where specified for oncology and targeted therapies.

    • Include tumor staging and prior systemic therapy records.
    • Ensure molecular testing reports are legible and dated.
    Documentation Required

    Required diagnostic documentation

    When molecular testing is required, submit documentation of diagnosis, stage (eg, locally advanced or metastatic), and results from an FDA‑approved or CLIA‑certified test (eg, KRAS G12C, EGFR exon 19/21, BRAF V600E/V600K).

    • Attach both the clinical diagnosis note and the companion diagnostic report.
    • For combination regimens, show the planned concomitant agents.
    Documentation Required

    BRAF mutation test and combination use

    For BRAF‑targeted combination use, include BRAF V600E or V600K mutation documentation by an FDA‑approved test (THxID‑BRAF Kit) or CLIA lab and confirm the combination regimen (eg, with encorafenib).

    • Attach the THxID‑BRAF Kit or equivalent CLIA report.
    • Provide the oncology treatment plan showing combination therapy.
    Documentation Required

    Diabetes diagnostic documentation

    For diabetes agents like Mounjaro or Ozempic, submit medical records confirming T2DM diagnosis or lab evidence (A1c ≥6.5%, FPG ≥126 mg/dL, or 2‑hour OGTT ≥200 mg/dL).

    • Include recent A1c or fasting glucose results.
    • Document prior diabetes medications and response.
    Documentation Required

    Fungal prophylaxis documentation

    For posaconazole prophylaxis, include documentation of high‑risk status (eg, HSCT with GVHD or prolonged neutropenia) or prior invasive fungal infection history for secondary prophylaxis.

    • Attach transplant or oncology treatment notes documenting neutropenia or GVHD.
    • Include prior fungal infection culture or treatment history if secondary prophylaxis.
    Documentation Required

    Arikayce required documentation

    For Arikayce, include medical records documenting failure to achieve ≥2 negative sputum cultures after a minimum 6 months of a multidrug background regimen and the infectious disease/pulmonology consult.

    • Provide sequential sputum culture results and dates of background antibiotics.
    • Attach specialist consultation confirming refractory MAC lung disease.
    Documentation Required

    Onychomycosis required documentation

    For onychomycosis topical agents, include KOH/culture/histology confirmation, documentation that lunula/matrix is not involved, and evidence of oral terbinafine trial/failure or contraindication for the specified durations.

    • Attach lab/biopsy reports and notes describing nail matrix involvement.
    • Provide terbinafine treatment dates and reason for failure/intolerance if applicable.
    Documentation Required

    Iron overload required documentation

    Include baseline ferritin and LIC/transfusion history for deferasirox requests; reauthorization requires evidence of reduction in ferritin or LIC from baseline as specified.

    • Provide baseline and follow‑up ferritin values and LIC when available.
    • Document transfusion volumes (≥100 mL/kg) for transfusional iron overload.
    Documentation Required

    Doptelet required documentation

    For Doptelet requests include baseline platelet counts and evidence of planned procedure for TPPP or prior TF/C/I to corticosteroids/IVIG/splenectomy for ITP, plus hematology consult documentation.

    • Attach platelet count labs and procedure scheduling documentation.
    • Include hematologist recommendation for therapy.
    Documentation Required

    Required laboratory documentation

    Provide required laboratory evidence (eg, Hgb/Hct within required timeframe, erythropoietin levels) for anemia indications; requests missing these labs risk denial.

    • Include Hgb/Hct within 30 days for CKD, within 2 weeks for chemotherapy indications.
    • Attach serum erythropoietin when indicated (≤500 mU/mL).
    Documentation Required

    Baseline biomarker / diagnostic documentation

    When baseline biomarker or diagnostic documentation is required (eg, blood eosinophils, histology for EoE), include these results and prior therapy trials as part of the PA submission.

    • Attach eosinophil counts, biopsy reports, HRCT, or other objective tests.
    • Document prior trials of indicated therapies and outcomes.
    Documentation Required

    Required medical information

    For each indication, submit medical records documenting diagnosis and supporting labs/tests (examples: Hgb/Hct for anemia, HRCT/biopsy for IPF, genetic/enzyme testing for Fabry disease).

    • Ensure all required test reports are included and dated within specified windows.
    • If criteria include specialist involvement, attach the consult or prescribing provider specialty.
    Documentation Required

    Required diagnostic test evidence

    Attach diagnostic test evidence (eg, HER2, EGFR, ROS1, KRAS, PIK3CA) performed by FDA‑approved or CLIA‑certified tests when required for the requested targeted therapy.

    • Include the assay name, result, and performing lab credentials.
    • For combination regimens, indicate planned partner drug(s).
    Documentation Required

    Required clinical documentation

    Provide clinical documentation and biomarker/mutation reports from FDA‑cleared or CLIA‑approved tests for therapies requiring companion diagnostics (eg, EGFR, KRAS, PIK3CA, CFTR tests).

    • Attach genetic/molecular reports that specifically identify the required mutation or genotype.
    • Include oncology or specialty notes confirming use in the indicated setting.
    Documentation Required

    Companion diagnostic requirement

    When companion diagnostics are required (eg, PIK3CA for Piqray, therascreen), include the FDA‑approved assay report or CLIA laboratory result with the PA.

    • Submit the therascreen PIK3CA RGQ PCR Kit report or equivalent CLIA result.
    • Confirm planned combination therapy (eg, fulvestrant for Piqray).
    Documentation Required

    Genetic testing requirement

    Genetic testing requirements (eg, for Pyrukynd) must be met — include molecular testing confirming required variant alleles and relevant lab thresholds (eg, Hgb ≤10 g/dL) in the authorization.

    • Attach full genetic report showing PKLR variants per criteria.
    • Include baseline hemoglobin and clinical notes supporting symptomatic anemia.
    Documentation Required

    Required medical records

    Provide medical records documenting diagnoses, symptom severity metrics (BSA, SCORAD, CDAI, stool frequency), and prior treatment trials/failures/contraindications as required for the indication.

    • Include objective severity measures (eg, CDAI >220 for Crohn's) when requested.
    • Attach prior therapy histories and specialist notes.
    Documentation Required

    Documentation for IV induction dosing

    For IV induction dosing (eg, certain IBD induction products), include documentation of disease severity and that induction dosing will follow FDA‑labeled weight‑based schedules.

    • Provide weight and dosing plan (260 mg ≤55 kg, 390 mg >55–85 kg, 520 mg >85 kg) for IV induction.
    • Include CDAI or stool frequency/lab evidence supporting induction.
    Documentation Required

    General documentation requirements

    Ensure required medical information includes specific diagnosis, evidence of prior therapy failure when specified, patient weight/age limits, and documentation of specialty prescribing or consultation.

    • Attach weight and age documentation where thresholds apply (eg, Steqeyma 90mg for >100 kg; Spevigo ≥40 kg).
    • Include specialist consult notes when mandated.
    Documentation Required

    Osteoporosis: required data elements

    For osteoporosis PA requests, include BMD T‑scores from lumbar spine, femoral neck, total hip, or one‑third radius, fracture history, TF/C/I to prior osteoporosis therapy, and FRAX probabilities when applicable.

    • Provide DEXA scan reports with exact T‑score readings.
    • Include prior osteoporosis medication history and fracture documentation.
    Documentation Required

    Testosterone: required labs and diagnosis

    For testosterone therapy, submit diagnosis of hypogonadism (male at birth) and biochemical confirmation with two pre‑treatment total testosterone levels <300 ng/dL (or free/bioavailable criteria) or qualifying conditions per the policy.

    • Include two baseline total T measurements and timing of draws.
    • Document any SHBG‑altering conditions and calculated free T if applicable.
    Documentation Required

    Tryngolza: required genetic and lab documentation

    For Tryngolza, include genetic confirmation of biallelic pathogenic variants in FCS genes or a NAFCS score ≥45, baseline fasting triglycerides ≥880 mg/dL, and prior therapy history/intolerance documentation.

    • Attach genetic testing or NAFCS scoring documentation.
    • Provide fasting TG level and prior triglyceride‑lowering therapy history.
    Documentation Required

    Lapatinib required information

    For lapatinib, submit documentation of HER2‑positive advanced/metastatic/recurrent breast cancer and the concomitant agent planned (trastuzumab, capecitabine, or aromatase inhibitor).

    • Attach HER2 testing report and treatment plan showing combination therapy.
    • Document prior HER2‑directed therapy if relevant.
    Documentation Required

    Tymlos documentation

    Tymlos PA submissions must include BMD T‑scores and history of low‑trauma fracture or TF/C/I to prior osteoporosis therapy; note the lifetime parathyroid hormone duration limit (≤24 months).

    • Provide DEXA reports and fracture records.
    • State cumulative prior parathyroid hormone therapy duration.
    Documentation Required

    Vowst documentation

    For Vowst, include documentation of recurrent CDI with a positive stool toxin test, history of ≥2 recurrences in 12 months, completion of required antibiotic course 2–4 days prior, and completion or plan for magnesium citrate bowel prep.

    • Attach stool toxin/toxigenic C. difficile test result and CDI history.
    • Confirm antibiotic and bowel prep completion dates in records.
    Denial Risk

    Missing required diagnosis information

    Failure to provide the required diagnosis (eg, CGD or severe malignant osteopetrosis for Actimmune) or the required supporting documentation may result in denial of the request.

    • Ensure diagnosis documentation is explicit and matches the listed criteria.
    • Attach specialist notes when the product criteria require a specialist.
    Denial Risk

    Lack of required diagnosis or failure to meet disease-specific criteria

    Requests lacking the required diagnosis or failing to meet disease‑specific criteria (for example, COPD diagnosis for arformoterol or MAC lung disease criteria for Arikayce) risk denial.

    • Confirm the requested product matches the documented diagnosis and disease criteria.
    • For Arikayce, include sputum culture history and specialist consultation.
    Denial Risk

    For ciclopirox nail lacquer, missing confirmed diagnostic testing

    For ciclopirox nail lacquer, absence of diagnostic confirmation (KOH, culture, or histology), lack of documentation that the lunula/matrix is not involved, or missing evidence of oral terbinafine trial/failure can lead to denial.

    • Provide KOH/culture/histology and a note addressing lunula involvement.
    • Document terbinafine trial duration or contraindication with dates.
    Denial Risk

    Diagnostic confirmation and nail matrix involvement

    Requests for onychomycosis agents may be denied if diagnostic confirmation (KOH, culture, or histology) is not provided or if the patient has lunula (nail matrix) involvement that precludes topical therapy.

    • Confirm nail matrix (lunula) involvement is absent in clinical notes.
    • Attach diagnostic laboratory reports.
    Denial Risk

    HAE diagnostic confirmation and monotherapy requirement

    For prophylactic C1‑INH products in HAE, denials can occur if diagnosis is not confirmed by low C1‑INH antigenic or functional levels or if the product is used in combination with other prophylactic agents.

    • Include C1‑INH antigenic and/or functional level reports below LLN.
    • State that prophylaxis will not be combined with other approved prophylactic agents.
    Denial Risk

    Prior therapy exclusion for ALK inhibitor-naïve requirement

    Requests for ALK‑positive NSCLC that document prior exposure to an ALK inhibitor may be denied for indications requiring ALK inhibitor‑naïve status; verify prior ALK therapy history before submission.

    • Document prior ALK agents and treatment dates; if previously treated, note indication for later‑line use only if criteria allow.
    • Attach ALK testing report and staging information.
    Denial Risk

    Documentation-based denials

    Requests lacking required laboratory evidence (eg, Hgb/Hct within the specified timeframe) or missing diagnosis documentation for the indicated condition may be denied; submit labs and dated clinical notes as specified.

    • Provide labs within the policy‑specified time window.
    • Attach clinician notes confirming the diagnosis and rationale for therapy.
    Denial Risk

    Missing required diagnostic evidence

    Missing required diagnostic information (for example, absent molecular mutation testing for targeted agents) may trigger denial — include the test reports performed by FDA‑approved or CLIA‑certified labs.

    • Attach the molecular diagnostic report showing the required mutation.
    • If testing was not performed, provide justification and consider ordering the test prior to PA submission.
    Denial Risk

    Missing required diagnostic or prior therapy documentation

    Lack of documented tumor mutation status (eg, KRAS G12C) or absence of required prior systemic therapy where specified may result in denial for oncology targeted therapies.

    • Provide mutation test report and prior systemic therapy records (lines of therapy).
    • Document combination partner therapy when required.
    Denial Risk

    Missing required diagnostic or treatment history

    Requests missing required molecular testing or treatment history (eg, KRAS G12C testing, prior systemic therapy) may be denied; include the specific mutation test report and prior therapy details.

    • Attach CLIA/FDA test report for the relevant mutation.
    • Include prior therapy regimens and dates.
    Denial Risk

    Missing required diagnostic test

    Absence of the required diagnostic test documentation (eg, lack of documented BRAF V600E/V600K mutation by an FDA‑approved or CLIA‑approved test) for melanoma or NSCLC indications can trigger denial.

    • Submit the THxID‑BRAF Kit or CLIA lab report confirming BRAF V600E/K status.
    • If unavailable, document alternative validated testing per policy.
    Denial Risk

    Missing sleep study documentation

    For armodafinil in OSA, absence of sleep study confirmation of obstructive respiratory events (unless a justification is provided) may lead to denial; include polysomnography results when available.

    • Attach sleep study showing ≥15 events/hour or ≥5 events/hour with qualifying symptoms, or provide documented justification if study not feasible.
    • Include clinical notes describing daytime symptoms and prior management.
    Denial Risk

    Missing required documentation of prior intensive induction and remission

    For AML maintenance agents (eg, Opipza/Onureg contexts), lack of documentation of prior intensive induction chemotherapy and achievement of CR or CRi may trigger denial; include oncology treatment records confirming prior induction and remission status.

    • Provide induction chemotherapy regimen details and documentation of CR/CRi.
    • If unable to complete curative therapy, include treating oncologist rationale.
    Denial Risk

    For PAH agents, missing right heart catheterization or current therapy documentation

    For PAH agents, absence of right heart catheterization confirmation or lack of documentation that the patient is currently on PAH therapy may result in denial; include right heart cath reports or current PAH medication records.

    • Attach right heart catheterization hemodynamics when available.
    • Document current PAH therapy if catheterization is not recent.

    Initial Authorization Requirements

    Reauthorization and Continuation Rules

    Step Therapy and Trial Requirements

    RequirementDetails
    Must document trial and failure (TF/C/I) of specified agents before approvalExample: For rheumatoid arthritis and other biologic indications, a minimum 3-month TF/C/I to one conventional therapy (methotrexate, leflunomide, or sulfasalazine) is required prior to biologic initiation.
    RequirementDetails / Examples
    Must document prior trials or contraindicationsExamples: For BPH (tadalafil), trial and failure, contraindication, or intolerance to an alpha‑blocker or a 5‑alpha reductase inhibitor is required; for schizophrenia agents, TF/C/I to two generic atypical antipsychotics required prior to coverage.
    RequirementPolicy language / scope
    Must document TF/C/I to listed comparators unless continuing prior therapyMany products require documented TF/C/I to specified comparator agents (e.g., two oral atypical antipsychotics for schizophrenia; minimum 4‑week TF/C/I to topical therapies for plaque psoriasis) unless the request is for continuation of previously authorized therapy.
    RequirementRequired duration or condition
    Prior therapies must be tried at specified durations or be contraindicated/intolerantExamples include: RA — minimum 3‑month TF/C/I to methotrexate/leflunomide/sulfasalazine; PJIA — minimum 6‑week TF/C/I to methotrexate or leflunomide; plaque psoriasis — minimum 4‑week TF/C/I to topical therapy.
    RequirementEvrysdi-specific condition
    Absence of concomitant chronic SMN-modifying therapy required; prior gene therapy allowed only with documented inadequate responseEvrysdi must not be used concurrently with other chronic SMN‑modifying therapies (e.g., nusinersen/Spinraza). If the patient previously received gene replacement therapy (e.g., onasemnogene abeparvovec/Zolgensma), coverage may be considered only with documentation of inadequate response as specified in the policy (baseline and follow‑up motor testing).
    RequirementDocumentation needed
    Evidence of prior trial and failure/contraindication/intolerance to required agents must be documentedProvider must submit medical records documenting the required prior therapy trials and reasons for TF/C/I (examples: RA prior DMARDs; Parkinson's intermittent OFF therapies trial failures). Lack of this documentation may result in denial.
    RequirementExamples / policy note
    Document trial and failure or contraindication/intoleranceFor systemic antifungals and acute migraine agents, the policy requires documentation of trial and failure or contraindication/intolerance to listed first‑line agents (e.g., prior oral terbinafine trial for onychomycosis; single triptan trial for DHE/acute migraine agents).
    RequirementJAK inhibitor / hydroxyurea
    Document HF/C/I to hydroxyurea for JAK inhibitor coverageFor polycythemia vera and related JAK inhibitor indications, the request must document trial and failure, contraindication, or intolerance to hydroxyurea prior to approval as specified in the product entry.
    RequirementPrior therapy step
    Step requiring prior trials of specific agents before approvalSeveral oncology and specialty drug entries mandate prior trials of listed agents (examples: Lonsurf requires prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy and anti‑VEGF therapy; other agents specify required systemic regimens before approval).
    RequirementAntipsychotic prior trials for Opipza / Opusmit
    Required trials of listed antipsychotics before OpipzaOpipza requires TF/C/I to specified prior antipsychotics: schizophrenia — TF/C/I to two listed oral atypical antipsychotics; MDD/autism/Tourette's branches specify required trials or intolerance to agents such as quetiapine and aripiprazole as detailed in the policy.
    RequirementTriptan requirement
    Single triptan trial required (or contraindication to all)For acute migraine agents (e.g., DHE, Ubrelvy, other specified products), the policy requires trial and failure or intolerance to one triptan (examples: eletriptan, rizatriptan, sumatriptan) or documentation of contraindication to all triptans prior to approval.
    RequirementPrior therapy trials
    Trials of listed prior therapies required before approvalMultiple psychiatric and other specialty indications require prior TF/C/I to enumerated agents before approval (Opipza/Opusmit examples: TF/C/I to specific antipsychotics; oncology and other products list prior systemic or targeted therapy requirements).
    RequirementPrior TF/C/I required
    Prior trial and failure/intolerance required before agent approval for several indicationsExamples: Many immunologic and rheumatologic products require documented prior TF/C/I to conventional DMARDs or TNF inhibitors (RA, PJIA, PsA) before advanced agents will be approved.
    RequirementBroad prior therapy expectations
    Required prior therapy before approval for many indicationsPolicy routinely requires documented TF/C/I to topical, systemic, or class‑specific therapies (e.g., topical corticosteroids, vitamin D analogs for psoriasis; conventional DMARDs for rheumatologic diseases) prior to coverage of higher‑tier agents.
    RequirementDocumentation of TF/C/I when specified
    Documentation of prior trial and failure/contraindication/intolerance when specifiedFor certain agents (e.g., trientine for Wilson's disease; teriparatide/Tymlos for osteoporosis), the policy requires TF/C/I to listed alternatives or evidence meeting fracture/BMD/FRAX criteria before approval.
    RequirementAlternatives TF/C/I
    Document TF/C/I to listed alternativesSeveral oncology and specialty agents require documentation that the patient tried and had TF/C/I to specified alternative therapies (examples in oncology entries referencing sunitinib, sorafenib, prior anti‑HER2 regimens, etc.).
    RequirementOsteoporosis prior therapy
    Must document TF/C/I to prior therapy when requiredTymlos and similar parathyroid hormone agents require documentation of TF/C/I to one osteoporosis treatment or qualifying fracture/BMD/FRAX criteria prior to approval; lifetime parathyroid hormone therapy duration limits apply (max 24 months).
    RequirementTrial / contraindication documentation
    Document trial and failure/intolerance or contraindicationAcute migraine and other acute agents require documentation of trial and failure or intolerance to a single triptan (or contraindication to all) prior to coverage; providers must record the trial and outcome.
    RequirementGeneral TF/C/I documentation
    Document trial and failure or contraindication/intoleranceSeveral agents (e.g., systemic antifungals, MS agents) require documentation that the patient tried and failed or could not tolerate listed prior therapies; supporting records must be submitted with PA requests.

    Site of Care Notes

    Billing Rule

    Infusion center / Part B vs Part D review

    Infusion center vs Part B/Part D site‑of‑care considerations apply to certain infusion products; verify billing pathway and include site‑of‑care details when applicable.

    • Examples: arformoterol, Ventavis — subject to Part B vs Part D review.
    Note

    PAH specialty prescriber and site context

    Hospital outpatient site is noted for PAH initial prescribing — ensure specialty prescriber involvement (pulmonologist or cardiologist) is documented for PAH agents.

    • Document pulmonologist or cardiologist prescribing/consultation for initial PAH requests.
    Billing Rule

    Ventavis — Part B vs Part D review

    Ventavis is subject to Part B vs Part D review; include site‑of‑care and billing plan details in the authorization request.

    • Confirm whether the administration will be billed under Part B or Part D and document accordingly.
    Billing Rule

    Vyjuvek — administration by HCP (site of care)

    Vyjuvek is applied by a healthcare professional and may be provided in an office or infusion center setting; document the planned administration setting.

    • Include a plan showing a healthcare professional will apply the medication and any site restrictions.

    Background and Scope

    This policy excerpt provides coverage and prior-authorization requirements for a broad set of pharmacy and specialty drugs on the Blue Cross Blue Shield – South Carolina formulary (Formulary ID: 25385, effective 12/01/2025). It defines product-specific coverage conditions (diagnosis confirmation, biomarker or genetic testing when required, age/weight limits), step-therapy expectations (trial and failure, contraindication, or intolerance — “TF/C/I” — to specified conventional therapies), and documentation needed to support approvals (e.g., recent lab values, imaging, pathology, or specialist consultation).

    Most products are available only when the clinical prerequisites listed in each entry are met; common elements across entries include: requirement for a documented diagnosis and indication-specific objective data, prescriber specialty recommendations for select agents, and authorization durations typically of 6 months initial for some biologic/acute starts and 12 months for maintenance or reauthorization. Continuation of previously authorized therapy is explicitly approvable when the patient demonstrates a positive clinical response. The document also notes exclusions and not-medically-necessary uses (for example, restrictions on combining certain classes such as injectable CGRP inhibitors for migraine prevention and exclusion of pyrimethamine for malaria prophylaxis).

    Providers requesting prior authorization should supply the diagnosis and the specific supporting clinical information required for the drug and indication (for example, genetic or biomarker test results performed by an FDA-cleared or CLIA-certified laboratory, recent lab thresholds, documentation of TF/C/I to listed comparators, and specialist consultation where indicated). Absent the required documentation or failure to meet the indication-specific criteria may result in denial.

    Terms and Diagnostic Test Requirements

    inv-341: TF/C/I
    DefinitionTF/C/I = trial and failure, contraindication, or intolerance to specified conventional therapies at maximally tolerated doses
    ApplicationUsed as step-therapy requirement for many biologic and specialty drug indications
    DocumentationPrior trial/TF/C/I must be documented for prior authorization
    inv-342: FGFR3 alteration (testing requirement)
    Testing requirementFGFR3 alteration must be detected by an FDA-approved test (therascreen FGFR RGQ RT-PCR Kit) or a CLIA-approved test
    Indication contextRequired for Balversa coverage in urothelial carcinoma
    DocumentationSubmit test performed by FDA-cleared assay or CLIA-certified laboratory
    inv-343: BRAF V600 mutation (testing requirement)
    BRAF V600 mutation testingBRAF V600E or V600K mutation must be detected by an FDA-approved test (THxID-BRAF Kit) or a CLIA-approved test
    Use-caseRequired for BRAF-targeted therapies (eg, Braftovi, Tafinlar combinations) in melanoma, NSCLC
    Combination requirementOften required to document planned combination (eg, with encorafenib or binimetinib) per product
    inv-344: BRAF V600E or V600K mutation
    Mutation typesBRAF V600E or V600K mutation
    Assay requirementDetected by FDA-approved THxID-BRAF Kit or CLIA-certified laboratory test
    IndicationsUsed to qualify patients for combination BRAF-directed regimens in melanoma and NSCLC
    inv-345: C1-INH deficiency or dysfunction (Type I or II HAE)
    Diagnostic confirmationC1-INH antigenic level below lower limit of normal OR C1-INH functional level below lower limit of normal
    IndicationRequired for prophylactic C1-INH products for hereditary angioedema (HAE)
    Therapy restrictionNot used in combination with other approved prophylactic HAE treatments
    inv-346: Eosinophilic asthma / type 2 inflammation
    Eosinophilic asthma threshold>= 150 cells/mcL (baseline blood eosinophils)
    COPD type 2 inflammation threshold>= 300 cells/mcL
    EoE relationEosinophil thresholds used to qualify for certain biologics; diagnostic biopsy required for EoE
    inv-347: Eosinophilic esophagitis (EoE)
    Histologic criterion>= 15 intraepithelial eosinophils per high power field
    Clinical requirementSymptoms of esophageal dysfunction and exclusion of other causes required
    Prior therapyTrial/failure/contraindication to an 8-week PPI or topical esophageal corticosteroid required for many approvals
    inv-348: SMN-modifying therapy
    SMN2 copy numberPatient has at least 2 copies of SMN2
    Ventilation statusNot dependent on invasive ventilation/tracheostomy and not on chronic non-invasive ventilation beyond naps/night
    Concurrent therapyNot to be used concomitantly with other chronic SMN-modifying therapies (eg, Spinraza)
    inv-349: EGFR activating mutation
    EGFR activating mutationsEGFR exon 19 deletions or exon 21 (L858R) substitution mutations
    Assay requirementDetected by FDA-approved or CLIA-certified test
    IndicationRequired for osimertinib/EGFR-targeted therapy coverage in metastatic NSCLC
    inv-350: ROS1 rearrangement
    ROS1 rearrangementROS1 rearrangement-positive tumor as detected by an FDA-approved or CLIA-certified test
    IndicationRequired for ROS1-targeted therapy coverage in NSCLC
    DocumentationSubmit FDA-cleared assay or CLIA laboratory result
    inv-351: CLIA-approved test / FDA-approved test
    Test performanceBiomarker/mutation testing must be performed using an FDA-approved assay or at a CLIA-certified facility
    ExamplesEGFR exon19/exon21, KRAS G12C, BRAF V600E/K, PIK3CA, FGFR2 fusions listed as examples in document
    Submission requirementProvide test name and laboratory documentation with prior authorization
    inv-352: FDA- or CLIA-approved test
    FDA- or CLIA-approved testsMolecular diagnostic assays must be FDA-approved or performed in CLIA-certified laboratories
    Use casesRequired for tumor mutation/fusion detection (eg, KRAS G12C, FGFR2, H3 K27M) for targeted therapy coverage
    DocumentationAttach laboratory report from FDA-cleared assay or CLIA lab with PA request
    inv-353: BRAF V600 mutation
    BRAF V600 mutationBRAF V600E or V600K mutant type
    Assay requirementDetected by FDA-approved THxID-BRAF Kit or CLIA-approved laboratory test
    Indication examplesRequired for melanoma and NSCLC BRAF-directed combination regimens
    inv-354: Progressive fibrosing ILD
    Progressive fibrosing ILD — imaging thresholdHRCT showing >= 10% lung volume with fibrotic features
    Progression definitionProgression defined by decline in FVC, worsening symptoms, or increased extent of fibrosis on imaging
    PrescriberPrescribed by or in consultation with pulmonologist for antifibrotic therapy
    inv-355: Homozygous F508del
    Homozygous F508del genotypeTwo copies of the F508del mutation in CFTR gene detected by FDA-cleared or CLIA-approved test
    Indication contextRequired for Orkambi coverage in cystic fibrosis
    PrescriberSpecialist (CF center or pulmonologist) involvement required
    inv-356: PIK3CA-mutated
    PIK3CA mutation detectionPIK3CA mutation must be detected by FDA-approved therascreen PIK3CA RGQ PCR Kit or a CLIA-certified test
    IndicationRequired for Piqray coverage in HR+/HER2- advanced breast cancer
    DocumentationSubmit companion diagnostic result with PA
    inv-357: PIK3CA-mutated breast cancer
    Disease subtypeHormone receptor-positive, HER2-negative breast cancer with PIK3CA mutation
    Test requirementMutation detected by FDA-approved or CLIA-certified test
    Therapy contextUsed in combination with fulvestrant per product labeling
    inv-358: Statin intolerance
    Statin intolerance definitionInability to tolerate at least two statins, with at least one started at the lowest starting daily dose, due to intolerable symptoms or clinically significant biomarker changes
    ApplicationUsed to qualify patients for PCSK9 inhibitor therapy when statins not tolerated
    inv-359: BSA
    Body surface area (BSA) thresholdsExamples: >=10% BSA for some atopic dermatitis criteria; >=3% BSA for plaque psoriasis
    UseBSA used as severity metric to qualify for dermatologic biologic therapies
    inv-360: CDAI
    CDAI threshold> 220
    ApplicationUsed to indicate moderately to severely active Crohn's disease for some IV induction and biologic criteria
    inv-361: hATTR amyloidosis with polyneuropathy
    hATTR polyneuropathy baseline scoresPND <= IIIb OR FAP stage 1–2 OR NIS between 10 and 130
    Diagnostic requirementPresence of a transthyretin (TTR) mutation (eg, V30M) and clinical signs/symptoms of neuropathy
    PrescriberPrescribed by or in consultation with neurologist
    inv-362: CDAI
    CDAI for CD eligibility> 220
    Other criteriaOr presence of objective clinical/lab features (frequent diarrhea, weight loss, complications, elevated CRP)
    inv-363: FRAX thresholds
    FRAX thresholds (US)Major osteoporotic fracture >= 20% ; Hip fracture >= 3%
    UseApplied to support treatment decisions for osteopenia/osteoporosis (eg, Tymlos, teriparatide)
    inv-364: Hypogonadism (HG) lab criteria
    Total testosterone thresholdTwo pre-treatment total T levels < 300 ng/dL
    Free/bioavailable testosteroneCalculated free/bioavailable T < 5 ng/dL when SHBG-altering conditions present
    Additional qualifiersOr history of bilateral orchiectomy, panhypopituitarism, or genetic causes of hypogonadism
    inv-365: Decompensated liver disease
    Decompensated liver disease definitionChild-Pugh Class B or C
    ApplicationExcludes patients with decompensated liver disease from certain HCV DAA therapies (eg, Vosevi) per criteria
    inv-366: Recurrent CDI
    Recurrent CDI definitionHistory of two or more recurrent episodes within 12 months with positive stool toxin or toxigenic C. difficile test
    Pre-treatment requirementsCompletion of recommended antibiotic course 2-4 days prior and bowel prep (magnesium citrate) before Vowst

    Policy Revision History

    2025-12-01policy_effective_dateLatest

    Formulary effective date updated to 12/01/2025 (Version 18) for multiple product coverage criteria entries